文献速递泌尿男性生殖肿瘤

p21阳性衰老基质细胞促进前列腺癌免疫抑制且可被衰老细胞清除疗法逆转

p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy.
PubMed 文献 · Cancer Discov · 2026-01-01

该研究利用前列腺癌患者样本和小鼠模型发现,p16+和p21+衰老细胞随恶性进展积累并与免疫抑制相关,单细胞测序显示p21+非肿瘤细胞SASP表达最高。清除p21+基质细胞可阻断SASP、逆转免疫抑制并延缓肿瘤生长,BCL-xL抑制剂可清除p21+基质衰老细胞、激活CD8+ T细胞并抑制肿瘤进展,且抑制BCL-xL或p21可增强抗PD-1疗效。

要点

  • p21+衰老基质细胞高表达SASP并与前列腺癌免疫抑制相关
  • BCL-xL抑制剂可清除p21+基质衰老细胞并激活抗肿瘤CD8+ T细胞
  • 抑制BCL-xL或p21可增强抗PD-1免疫检查点阻断疗效

核心结论

  • 靶向p21+衰老基质细胞群可通过激活抗肿瘤免疫和增强免疫治疗 outcomes 在晚期前列腺癌中产生治疗获益。

研究设计与样本

  • 使用前列腺癌患者样本和小鼠模型开展研究,并结合单细胞测序分析衰老细胞群体。

主要发现

  • p16+和p21+衰老细胞在整个恶性进展过程中积累并与免疫抑制相关。
  • 单细胞测序显示p16和p21标记不同的上皮和基质衰老群体,其中p21+非肿瘤细胞表达最高水平的SASP。
  • 清除p21+基质细胞可阻断SASP、逆转免疫抑制并减缓肿瘤生长。
  • 衰老细胞清除剂BCL-xL抑制剂可清除p21+基质衰老细胞,重新激活抗肿瘤CD8+ T细胞免疫并抑制小鼠前列腺肿瘤进展。
  • 抑制BCL-xL或p21可在临床前前列腺癌模型中增强抗PD-1免疫检查点阻断(ICB)的效果。

临床怎么用

  • 靶向p21+衰老基质细胞可能成为晚期前列腺癌的治疗策略,通过激活抗肿瘤免疫并增强抗PD-1免疫治疗疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Cellular senescence is a well-established tumor-suppressive cell-cycle arrest program. However, chronic inflammation through the senescence-associated secretory phenotype (SASP) can alternatively drive immune suppression and cancer progression. Using prostate cancer patient samples and murine models, we find p16+ and p21+ senescent cells accumulate throughout malignant progression and associate with immune suppression. Single-cell sequencing revealed that p16 and p21 mark distinct epithelial and stromal senescent populations, with p21+ nontumor cells expressing the highest SASP. p21+ stromal cell removal blocked the SASP to reverse immune suppression and slow tumor growth. Senolytic BCL-xL inhibitor treatment could clear p21+ stromal senescent cells, reactivating antitumor CD8+ T-cell immunity and inhibiting prostate tumor progression in mice. Suppression of BCL-xL or p21 also potentiated anti-PD-1 immune checkpoint blockade (ICB) in preclinical prostate cancer models. Our findings demonstrate that targeting p21+ senescent stromal populations can yield therapeutic benefits in advanced prostate cancer through activating antitumor immunity and enhancing immunotherapy outcomes. SIGNIFICANCE: Senescent cells accumulate in the tumor and stroma throughout prostate cancer progression and are associated with immune suppression in patients and mice. Senolytic strategies to clear p21+ senescent stromal cells can prevent prostate cancer progression and reactive cytotoxic T-cell immunity to potentiate anti-PD-1 ICB in advanced disease.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Zhou L, DeMarco KD, Murphy KC, et al. p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy. Cancer Discov. 2026. PMID: 41135083. doi:10.1158/2159-8290.CD-25-1212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。